Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $47.4 million, down from $69.4 million in Q2 2024. Excluding high volume Clean Cap, base revenue increased by 5% year-over-year [19][20] - GAAP net loss before non-controlling interests was $69.8 million for Q2 2025, compared to a loss of $18.4 million in Q2 2024 [20] - Adjusted EBITDA was negative $10.4 million for Q2 2025, down from a positive $13 million in Q2 2024 [21] - Basic and diluted EPS for Q2 2025 was a loss of $0.27 per share, compared to a loss of $0.07 per share in Q2 2024 [21] Business Line Data and Key Metrics Changes - Nucleic Acid Production (NAP) segment revenue was $31.1 million in Q2 2025, with base NAP business excluding high volume Clean Cap up 3% year-over-year [23] - Biologics Safety Testing (BST) segment revenue was $16.3 million in Q2 2025, reflecting a 10% year-over-year increase [24] - Adjusted EBITDA for BST was $10.9 million, resulting in an adjusted EBITDA margin of 67% [24] Market Data and Key Metrics Changes - Revenue by customer type in Q2 2025: 28% biopharma, 30% life sciences and diagnostics, 8% academia, 7% CRO, CMO, CDMO, and 27% to distributors [19] - Revenue by geography: 65% North America, 18% EMEA, 12% Asia Pacific (excluding China), and 5% in China [19] Company Strategy and Development Direction - The company is committed to improving operational excellence and execution through a restructuring plan aimed at reducing annualized expenses by over $15 million [6][7] - Focus on revenue diversification and growth across business segments, particularly in BST and NAP, with investments in new analytical products [10][11] - The company aims to return to sustainable positive adjusted EBITDA and free cash flow by 2026 [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the need for a stronger culture of accountability and operational discipline to drive results [5] - The CEO expressed optimism about the company's future, emphasizing the potential for growth and profitability despite current challenges [15] - The leadership team is focused on stabilizing the organization and exploring further growth opportunities post-restructuring [111] Other Important Information - The company has initiated a comprehensive business review and has withdrawn prior guidance for 2025, planning to reinstate guidance after completing the review [27] - Anticipated restructuring charges of approximately $8 million to $9 million in 2025, primarily for employee severance and related expenses [26] Q&A Session Summary Question: Guidance philosophy and visibility for 2026 targets - Management is focused on controlling costs and gaining confidence in the numbers shared, with no specific red flags indicating incorrect guidance [36][40] Question: Durability of BST improvement and pull forward dynamics - BST showed strong growth, with no significant pull forward dynamics from China or Asia impacting Q2 results [41][43] Question: Growth potential in China - Management expects China to become a growth driver as relations between the U.S. and China improve [47] Question: Impact of tariffs on CDMO business - Currently, there has been little movement regarding tariffs, but potential opportunities exist if tariffs lead to U.S. production shifts [51] Question: Positive surprises and challenges in the business review - Management was surprised by the extent of expenditures and the loyalty of customers in the preclinical to phase three segments [56][58] Question: E-commerce revenue potential - E-commerce currently represents a small percentage of revenue, but management sees significant potential for growth in this area [75][78] Question: Long-term margin potential - Management aims to restore profitability and free cash flow before addressing long-term margin targets [92][94]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $57 million, aligning with expectations, and full year revenues of $259 million, near the midpoint of the previously stated range of $255 million to $265 million [10] - GAAP net loss before non-controlling interests was $46 million for Q4 2024, compared to a loss of $110 million in Q4 2023, while the annual net loss was $260 million, up from $138 million in 2023 [12] - Adjusted EBITDA for Q4 2024 was a negative $1 million, down from $21 million in Q4 2023, with a full year adjusted EBITDA of $36 million, reflecting a margin of 14% [12][13] Business Line Data and Key Metrics Changes - The Biologic Safety Testing segment generated $15 million in Q4 and $63 million for the full year, with an adjusted EBITDA margin of approximately 70% [10][17] - The Nucleic Acid Production segment reported revenues of $42 million in Q4, including $14 million from high volume clean cap sales, and $196 million for the full year, with an adjusted EBITDA margin of 26% [10][17] Market Data and Key Metrics Changes - Revenue breakdown by customer type for 2024 showed 48% from biopharma, 25% from life sciences and diagnostics, 5% from CROs, CMOs, and CDMOs, 4% from academia, and 18% through distributors [11] - The company’s exposure to China was $13.6 million for the full year, with expectations for flat growth in 2025 [69] Company Strategy and Development Direction - The company is focused on returning its base business to growth, anticipating revenues of $185 million to $205 million for 2025, excluding high volume clean cap [19][20] - Strategic investments include expanding commercial footprint, enhancing intellectual property protection, and integrating recent acquisitions to drive growth in the discovery area [30][63] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in forecasting due to market dynamics but expressed confidence in the company’s capabilities and growth opportunities [19][24] - The company is enhancing visibility into customer clinical programs to better predict sales and manage operations [27][35] Other Important Information - The company ended 2024 with $322 million in cash and $300 million in long-term debt, resulting in a net cash position of $22 million [14] - Capital expenditures for 2024 were $30 million, with expectations for a decline to $15 million to $20 million in 2025 [23][15] Q&A Session Summary Question: Can you provide guidance on gross margins for 2025? - Management indicated that the cost structure for 2025 will remain consistent with 2024, with fixed costs around $200 million and variable costs expected to range between 10% to 12% [46][47] Question: How is the company improving visibility with key customers? - Management noted that new agreements include mandatory disclosure requirements for clinical trial milestones, which should enhance visibility into customer programs [52][53] Question: What are the expectations for segment growth and revenue cadence? - Management expects Q1 2025 revenues to be between $43 million to $45 million, with growth anticipated in the back half of the year driven by acquisitions and new product introductions [56][58] Question: What are the capital allocation priorities for 2025? - The company plans to focus on reducing cash interest expenses and is open to evaluating M&A opportunities that align with their strategic goals [62][63] Question: How much of the revenue forecast is related to COVID vaccine contributions? - Management stated that the forecast excludes any contributions from COVID-related revenues, reflecting a shift in focus to base business growth [80][82] Question: What percentage of revenue did the top 10 customers comprise for 2024? - The top 10 customers accounted for 46% of revenue in 2024, showing a gradual diversification from 48% in 2023 [84]